<p>MAIA Biotechnology（NYSEAMERICAN:MAIA - 獲取免費報告）預計將在 2026 年 5 月 8 日星期五市場開盤前發佈其 2026 年第一季度財報。分析師預計該公司本季度每股收益為（$0.18）。投資者可以查看該公司即將發佈的 2026 年第一季度財報摘要頁面，以獲取關於定於 2026 年 5 月 8 日下午 4:00（東部時間）的電話會議的最新詳情。</p>
<p>獲取 <strong>MAIA Biotechnology</strong> 的提醒：</p>
<p>MAIA Biotechnology（NYSEAMERICAN:MAIA - 獲取免費報告）最近一次發佈季度財報是在 3 月 23 日星期一。該公司報告本季度每股收益為（$0.08），超過分析師一致預期的（$0.13），超出幅度為$0.05。</p>
<h2>MAIA Biotechnology 股票表現</h2>
<p>NYSEAMERICAN MAIA 在星期五的開盤價為$1.33。MAIA Biotechnology 的 52 周最低價為$0.87，52 周最高價為$3.19。該股票的市值為 8069 萬美元，市盈率為-1.93，貝塔值為 0.30。該股票的 50 日移動平均價為$1.51，200 日移動平均價為$1.52。</p>
<h2>MAIA Biotechnology 的機構交易</h2>
<p>大型投資者最近對該公司的持倉進行了調整。Marshall Wace LLP 在第二季度購買了 MAIA Biotechnology 的新股份，價值約為$29,000。Jane Street Group LLC 在第二季度獲得了 MAIA Biotechnology 的新頭寸，價值$52,000。最後，Geode Capital Management LLC 在第二季度將其在 MAIA Biotechnology 的股份增加了 3.6%。Geode Capital Management LLC 目前擁有該公司 222,183 股股票，價值$400,000，在此期間又購買了 7,746 股。機構投資者持有該公司 5.65% 的股票。</p>
<h2>關於 MAIA Biotechnology</h2>
<p>（獲取免費報告）</p>
<p>MAIA Biotechnology, Inc 是一家臨牀階段的生物製藥公司，開發一種專有平台，用於單克隆抗體與診斷和治療放射性同位素的特定位點結合。通過利用精確放射化學，該公司旨在增強基於抗體的成像劑和靶向放射治療的安全性和有效性。其方法旨在通過 PET 成像提供高對比度的腫瘤可視化，以及在腫瘤學適應症中實現集中細胞毒性。</p>
<p>該公司的產品管線包括多個抗體 - 放射性示蹤劑候選藥物，優化用於檢測不同的腫瘤生物標誌物，前臨牀數據表明其靶向特異性和藥代動力學優於傳統方法。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過 MAIA Biotechnology</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5ZU0VBTUVSSUNBTiZTeW1ib2w9TUFJQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5ZU0VBTUVSSUNBTiZTeW1ib2w9TUFJQQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 MAIA Biotechnology 嗎？</h2>
<p>在考慮 MAIA Biotechnology 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而 MAIA Biotechnology 並不在名單上。</p>
<p>雖然 MAIA Biotechnology 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

MAIA

標普生物技術 ETF - SPDR

紐交所高增長板生物技術指數 ETF - First Trust

生物科技 ETF - VanEck Vectors

納斯達克生物科技指數 ETF - iShares Nasdaq

動態生物技術與基因組 ETF - Invesco

標普生物技術 3 倍做多 - Direxion

基因改革 ETF - ARK

醫藥突破 ETF - ALPS

<p>MAIA Biotechnology（NYSEAMERICAN:MAIA）將於 5 月 8 日發佈 2026 年第一季度財報，分析師預測每股虧損為 0.18 美元。該公司此前報告每股虧損 0.08 美元，超出預期。MAIA 的股票開盤價為 1.33 美元，市值為 8069 萬美元。機構投資者持有該股票的 5.65%，最近 Marshall Wace LLP 和 Jane Street Group LLC 進行了增持。MAIA 專注於開發用於癌症治療和成像的單克隆抗體偶聯物</p>

<p>MAIA Biotechnology (NYSEAMERICAN:MAIA - Get Free Report) is anticipated to issue its Q1 2026 results before the market opens on Friday, May 8th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter. Investors can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Friday, May 8, 2026 at 4:00 PM ET.</p>
<div class="lb-trans"><p>MAIA Biotechnology（NYSEAMERICAN:MAIA - 獲取免費報告）預計將在 2026 年 5 月 8 日星期五市場開盤前發佈其 2026 年第一季度財報。分析師預計該公司本季度每股收益為（$0.18）。投資者可以查看該公司即將發佈的 2026 年第一季度財報摘要頁面，以獲取關於定於 2026 年 5 月 8 日下午 4:00（東部時間）的電話會議的最新詳情。</p>
</div><p>Get <strong>MAIA Biotechnology</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>MAIA Biotechnology</strong> 的提醒：</p>
</div><p>MAIA Biotechnology (NYSEAMERICAN:MAIA - Get Free Report) last posted its quarterly earnings data on Monday, March 23rd. The company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.13) by $0.05.</p>
<div class="lb-trans"><p>MAIA Biotechnology（NYSEAMERICAN:MAIA - 獲取免費報告）最近一次發佈季度財報是在 3 月 23 日星期一。該公司報告本季度每股收益為（$0.08），超過分析師一致預期的（$0.13），超出幅度為$0.05。</p>
</div><h2>MAIA Biotechnology Stock Performance</h2>
<div class="lb-trans"><h2>MAIA Biotechnology 股票表現</h2>
</div><p>NYSEAMERICAN MAIA opened at $1.33 on Friday. MAIA Biotechnology has a 52 week low of $0.87 and a 52 week high of $3.19. The stock has a market capitalization of $80.69 million, a P/E ratio of -1.93 and a beta of 0.30. The stock has a fifty day moving average of $1.51 and a 200-day moving average of $1.52.</p>
<div class="lb-trans"><p>NYSEAMERICAN MAIA 在星期五的開盤價為$1.33。MAIA Biotechnology 的 52 周最低價為$0.87，52 周最高價為$3.19。該股票的市值為 8069 萬美元，市盈率為-1.93，貝塔值為 0.30。該股票的 50 日移動平均價為$1.51，200 日移動平均價為$1.52。</p>
</div><h2>Institutional Trading of MAIA Biotechnology</h2>
<div class="lb-trans"><h2>MAIA Biotechnology 的機構交易</h2>
</div><p>Large investors have recently made changes to their positions in the company. Marshall Wace LLP bought a new stake in shares of MAIA Biotechnology in the second quarter worth about $29,000. Jane Street Group LLC acquired a new position in MAIA Biotechnology in the 2nd quarter worth $52,000. Finally, Geode Capital Management LLC raised its stake in shares of MAIA Biotechnology by 3.6% in the 2nd quarter. Geode Capital Management LLC now owns 222,183 shares of the company's stock valued at $400,000 after purchasing an additional 7,746 shares during the period. Institutional investors own 5.65% of the company's stock.</p>
<div class="lb-trans"><p>大型投資者最近對該公司的持倉進行了調整。Marshall Wace LLP 在第二季度購買了 MAIA Biotechnology 的新股份，價值約為$29,000。Jane Street Group LLC 在第二季度獲得了 MAIA Biotechnology 的新頭寸，價值$52,000。最後，Geode Capital Management LLC 在第二季度將其在 MAIA Biotechnology 的股份增加了 3.6%。Geode Capital Management LLC 目前擁有該公司 222,183 股股票，價值$400,000，在此期間又購買了 7,746 股。機構投資者持有該公司 5.65% 的股票。</p>
</div><h2>About MAIA Biotechnology</h2>
<div class="lb-trans"><h2>關於 MAIA Biotechnology</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.</p>
<div class="lb-trans"><p>MAIA Biotechnology, Inc 是一家臨牀階段的生物製藥公司，開發一種專有平台，用於單克隆抗體與診斷和治療放射性同位素的特定位點結合。通過利用精確放射化學，該公司旨在增強基於抗體的成像劑和靶向放射治療的安全性和有效性。其方法旨在通過 PET 成像提供高對比度的腫瘤可視化，以及在腫瘤學適應症中實現集中細胞毒性。</p>
</div><p>The company's pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.</p>
<div class="lb-trans"><p>該公司的產品管線包括多個抗體 - 放射性示蹤劑候選藥物，優化用於檢測不同的腫瘤生物標誌物，前臨牀數據表明其靶向特異性和藥代動力學優於傳統方法。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than MAIA Biotechnology</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 MAIA Biotechnology</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5ZU0VBTUVSSUNBTiZTeW1ib2w9TUFJQQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NYSEAMERICAN&amp;Symbol=MAIA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in MAIA Biotechnology Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 MAIA Biotechnology 嗎？</h2>
</div><p>Before you consider MAIA Biotechnology, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 MAIA Biotechnology 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MAIA Biotechnology wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而 MAIA Biotechnology 並不在名單上。</p>
</div><p>While MAIA Biotechnology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 MAIA Biotechnology 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

MAIA Biotechnology (MAIA) Projected to Post Quarterly Earnings on Friday

Market Beat

MAIA Biotech

MAIA Biotech（MAIA）預計將在週五發佈季度財報